-
KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
31 May 2025 12:30 GMT
… breast cancer (TNBC)
Triple-negative breast cancer is the most aggressive type of breast cancer … breast cancer. Approximately 10-15% of patients with breast cancer … are diagnosed with TNBC. While some breast cancers … followed by doxorubicin or …
-
Biohybrids of Anoxia-Targeted Bacteria/MDPP for Enabling Targeted Synergistic Immunotherapy and Chemotherapy Against Breast Tumors
27 May 2025 12:02 GMT
… management of malignant breast tumors.6–8
To … oxaliplatin, paclitaxel, and doxorubicin.13–15 Additionally, MSNs … the odds in advanced breast cancer with combination immunotherapy: … cancer-associated fibroblasts promotes breast cancer cell proliferation and …
-
UP-Developed Model Shows Promise in Detecting Early Signs of Metastasis In Breast Cancer Patients
26 May 2025 11:46 GMT
… lung cancer.
Aggressive breast cancers can spread to … helping explain why breast cancer patients with LVI … better for aggressive breast cancer,” said corresponding author … is associated with doxorubicin resistance in breast cancer. Laboratory Investigation, …
-
Aaptamine Alters Vimentin Expression and Migration Capability of Triple-Negative Breast Cancer Cells
21 May 2025 22:06 GMT
… breast cancer cells.
Methods: The triple-negative breast cancer … Zhang D. Doxorubicin promotes breast cancer cell migration and … breast cancer and pathological response after neoadjuvant chemotherapy. Breast Cancer. … in vivo in breast tumors. Mol Carcinog. …
-
Pertuzumab Combo Reduces Risk of Death in HER2+ Early-Stage Breast Cancer
14 May 2025 00:44 GMT
… Society for Medical Oncology (ESMO) Breast Cancer Congress.
"After 10 … 50 mg/m2 of doxorubicin, and 500 to 600 … mg/m2 of doxorubicin or 90 to 120 mg … receptor 2 (HER2)-positive primary breast cancer (APHINITY). ClinicalTrials.gov. Updated January …
-
T-DXd Regimen Improves pCR in Early HER2+ Breast Cancer
13 May 2025 20:08 GMT
… advanced, HER2-positive early breast cancer experienced a clinically meaningful … of care of doxorubicin and cyclophosphamide followed … comparing T-DXd vs doxorubicin and cyclophosphamide followed … documented HER2-positive early breast cancer, have an ECOG …
-
Ten-Year APHINITY Data Show Genentech’s Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer
13 May 2025 05:15 GMT
… for Medical Oncology Breast Cancer Congress.
“The … the chemotherapy drugs doxorubicin, cyclophosphamide, and … in Breast Cancer
Genentech has been advancing breast cancer research … -negative breast cancers. As our understanding of breast cancer biology …
-
Strategic Optimization of Nanoparticle Characteristics to Enhance Tumor Targeting and Doxorubicin Delivery
20 May 2025 21:47 GMT
… . Chemotherapeutics such as doxorubicin (Dox), epirubicin, paclitaxel … cancers, including breast cancer,3 lung cancer … murine breast cancer cells, MDA MB231 human breast cancer cells, … immunogenic chemotherapeutics in breast cancer. J Breast Cancer. 2019;22 …
-
Your Guide to Treatments for Breast Cancer: Chemo, Radiation, and…
08 May 2025 19:39 GMT
… cells. Not all breast cancers need chemotherapy, … approach.
Inoperable breast cancer, widely metastasized breast cancer, and … used in breast cancer treatment include:
doxorubicin
epirubicin
… techniques available?
Breast cancer treatment almost always …
-
Neoadjuvant Trastuzumab Deruxtecan Improves Pathologic Complete Response in Patients With HER2+ Early Breast Cancer
08 May 2025 16:46 GMT
… care (dose-dense doxorubicin and cyclophosphamide followed by … positive (HER2+) early-stage breast cancer (eBC). The data … patients with HER2+ metastatic breast cancer. Pharmacy Times. April 21 … -patients-with-her2-metastatic-breast-cancer
3. ENHERTU® followed …
About
© 1995-2025